10:16 AM EDT, 03/13/2026 (MT Newswires) -- Sana Biotechnology ( SANA ) said Friday that 14-month follow-up data from a first-in-human study showed that hypoimmune-modified islet cells survived and continued to produce insulin in a type 1 diabetes patient without requiring immunosuppressing drugs.

The transplanted cells maintained their function, evaded immune detection, and presented no safety issues over the 14-month period, with the patient achieving tighter glycemic control between 12 and 14 months, the company said.

Sana Biotechnology ( SANA ) said it plans to submit an investigational new drug application for SC451, its stem cell-derived islet cell therapy, to begin a phase 1 clinical trial later this year.

Shares of the company were up 5.7% in Friday trading.

Price: 3.27, Change: +0.18, Percent Change: +5.70